Learn More
OBJECTIVE Despite advances in cervical cancer prevention and diagnosis, outcomes for patients given a diagnosis of advanced and recurrent disease are poor. In the GOG240 trial, the addition of(More)
362 Background: Bevacizumab (BEV), a humanized anti-VEGF monoclonal antibody, has demonstrated clinical efficacy in combination with 5-FU-based regimens in patients with metastatic colorectal cancer.(More)
3509 Background: The therapeutic impact of Bev plus either FOLFOX4 or XELOX in the adjuvant setting was evaluated in the AVANT trial. First efficacy findings were presented at ASCO GI 2011. Here we(More)
  • 1